Baptiste Abbar
About
Baptiste Abbar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Baptiste Abbar has authored 27 papers receiving a total of 397 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Baptiste Abbar's work include Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Treatments and Mutations (6 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Baptiste Abbar is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Treatments and Mutations (6 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Baptiste Abbar collaborates with scholars based in France, United States and China. Baptiste Abbar's co-authors include Joe‐Elie Salem, Solenn Brosseau, Antoine Khalil, Gérard Zalcman, Jean‐Philippe Spano, Céline Namour, V. Gounant, Johan Pluvy, Sandra Assoun and Nathalie Théou–Anton and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Clinical Pharmacology & Therapeutics.
In The Last Decade
Baptiste Abbar
20 papers receiving 389 citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baptiste Abbar France | 10 | 291 | 135 | 61 | 58 | 47 | 27 | 397 | ||
| Mitchell S. von Itzstein United States | 11 | 222 0.8× | 101 0.7× | 42 0.7× | 60 1.0× | 28 0.6× | 32 | 344 | ||
| Ramy Saleh Canada | 13 | 187 0.6× | 133 1.0× | 59 1.0× | 46 0.8× | 94 2.0× | 57 | 397 | ||
| Sarah Yentz United States | 10 | 255 0.9× | 119 0.9× | 47 0.8× | 50 0.9× | 38 0.8× | 32 | 401 | ||
| Taher Abu Hejleh United States | 11 | 254 0.9× | 158 1.2× | 121 2.0× | 35 0.6× | 67 1.4× | 45 | 445 | ||
| Abdel‐Ghani Azzouqa United States | 6 | 149 0.5× | 120 0.9× | 98 1.6× | 32 0.6× | 43 0.9× | 12 | 306 | ||
| Pranshu Bansal United States | 11 | 289 1.0× | 218 1.6× | 121 2.0× | 67 1.2× | 62 1.3× | 21 | 510 | ||
| Nathalie Letarte Canada | 10 | 221 0.8× | 141 1.0× | 137 2.2× | 52 0.9× | 33 0.7× | 26 | 477 | ||
| Hasna Bouchaab Switzerland | 12 | 299 1.0× | 217 1.6× | 77 1.3× | 57 1.0× | 22 0.5× | 43 | 530 | ||
| Shanthi Sivendran United States | 11 | 167 0.6× | 83 0.6× | 94 1.5× | 40 0.7× | 30 0.6× | 28 | 410 | ||
| Sonam Puri United States | 12 | 324 1.1× | 176 1.3× | 149 2.4× | 67 1.2× | 53 1.1× | 64 | 517 |
Countries citing papers authored by Baptiste Abbar
Since
Specialization
Citations
This map shows the geographic impact of Baptiste Abbar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baptiste Abbar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baptiste Abbar more than expected).
Fields of papers citing papers by Baptiste Abbar
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Baptiste Abbar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baptiste Abbar. The network helps show where Baptiste Abbar may publish in the future.
Co-authorship network of co-authors of Baptiste Abbar
This figure shows the co-authorship network connecting the top 25 collaborators of Baptiste Abbar. A scholar is included among the top collaborators of Baptiste Abbar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Baptiste Abbar. Baptiste Abbar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Boussouar, Samia, Etienne Charpentier, Baptiste Abbar, et al.. (2025). Case Report: Immune checkpoint-inhibitor related myotoxicity monitoring using a comprehensive cardiothoracic MRI approach: insights from a clinical case. Frontiers in Cardiovascular Medicine. 12. 1527048–1527048.
2.
Laurent, L. J. M., Baptiste Abbar, Kévin Bihan, et al.. (2025). Comedications Associated with Immune‐Related Adverse Events from Immune‐Checkpoint Inhibitors. Clinical Pharmacology & Therapeutics. 118(3). 593–599.
3.
Gougis, Paul, et al.. (2025). Prognosis and Phenotypes of Advanced Head and Neck Carcinoma Associated With Hypercalcemia. Head & Neck. 47(8). 2174–2182.
4.
Bailly, Guillaume, et al.. (2025). Rechallenge After Severe Immune Checkpoint Inhibitor Myocarditis. JACC CardioOncology. 7(3). 300–304.
5.
Lv, Yan, et al.. (2025). Development and validation of multi-sequence magnetic resonance imaging radiomics models for predicting tumor response to radiotherapy in locally advanced non-small cell lung cancer. Journal of Thoracic Disease. 17(3). 1684–1697.
6.
Dumont, Clément, Guilhem Roubaud, Damien Pouessel, et al.. (2025). Feasibility and efficacy of cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer in older patients: A retrospective French GETUG study.. Journal of Clinical Oncology. 43(5_suppl). 735–735.
7.
Gougis, Paul, Floriane Jochum, Baptiste Abbar, et al.. (2024). Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective. EClinicalMedicine. 70. 102536–102536.
8.
Gougis, Paul, Anne‐Sophie Hamy, Floriane Jochum, et al.. (2024). Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns. JAMA Network Open. 7(4). e245625–e245625.
9.
Gougis, Paul, et al.. (2024). Radiotherapy for oligoprogressive disease in non-small cell lung cancer treated with pembrolizumab in first-line setting: a retrospective study. Translational Lung Cancer Research. 13(12). 3603–3615.
10.
Gougis, Paul, Arthur Géraud, Marc Hilmi, et al.. (2022). Cytochrome P-450-mediated herb and food–drug interactions can be identified in cancer patients through patient self-reporting with a tablet application: results of a prospective observational study. ESMO Open. 7(6). 100650–100650.
11.
Swalduz, Aurélie, I. Monnet, Florian Guisier, et al.. (2022). 995P Effectiveness of combination of osimertinib with another targeted therapy in advanced EGFR mutated non-small cell lung cancer harbouring other oncogenic drivers: The real-world COMPOSIT study. Annals of Oncology. 33. S1008–S1008.
12.
Nguyen, Lee S., Marie Bretagne, Jennifer Arrondeau, et al.. (2022). Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for ImmunoTherapy of Cancer. 10(4). e004699–e004699.
13.
Canellas, Anthony, Baptiste Abbar, Marianne Veyri, et al.. (2021). Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy. JTO Clinical and Research Reports. 2(11). 100247–100247.
14.
Lavolé, A., Julien Mazières, S. Schneider, et al.. (2021). Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial. Lung Cancer. 158. 146–150.
15.
Gougis, Paul, Fleur Cohen‐Aubart, Luca Campedel, et al.. (2021). Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring. Journal of Pharmaceutical and Biomedical Analysis. 197. 113968–113968.
16.
Lavolé, A., Julien Mazières, S. Schneider, et al.. (2020). 1389P IFCT-1602 CHIVA2 phase II trial: Nivolumab in previously treated HIV-patients with advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 31. S882–S883.
17.
Abbar, Baptiste, Marianne Veyri, Caroline Solas, Isabelle Poizot‐Martin, & Jean‐Philippe Spano. (2020). VIH et cancer : mise au point en 2020. Bulletin du Cancer. 107(1). 21–29.
18.
Abbar, Baptiste, Paul Gougis, Sandra Assoun, et al.. (2020). Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. Lung Cancer. 152. 109–118.
19.
Abbar, Baptiste, Marine Baron, Christine Katlama, et al.. (2019). Immune checkpoint inhibitors in people living with HIV: what about anti-HIV effects?. AIDS. 34(2). 167–175.
20.
Assoun, Sandra, Nathalie Théou–Anton, Aurélie Cazes, et al.. (2019). Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. Lung Cancer. 132. 65–71.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mitchell S. von Itzstein Breakdown of academic impact, for papers by Ramy Saleh Breakdown of academic impact, for papers by Sarah Yentz Breakdown of academic impact, for papers by Taher Abu Hejleh Breakdown of academic impact, for papers by Abdel‐Ghani Azzouqa Breakdown of academic impact, for papers by Pranshu Bansal Breakdown of academic impact, for papers by Nathalie Letarte Breakdown of academic impact, for papers by Hasna Bouchaab Breakdown of academic impact, for papers by Shanthi Sivendran Breakdown of academic impact, for papers by Sonam Puri